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Globally, cervical cancer is the third most common cancer in women and impacts 275,000 women death each year meaning a woman will die due to cervical cancer every two minutes. 1 Cervical cancer is the second most common cancer among Indonesian women, after breast cancer. 2 Thus, it is important for patient, family and cancer service institution to know the survival probability. Our last data about cervical cancer survival was studied over 10 years ago. 3 During the time period, we observed many improvements in quality of cancer care in our institution such as cervical cancer screening, additional chemotherapy on advanced stages and insurance coverage (national insurance such as GAKIN/Jamkesmas). 4 Therefore, this study was undertaken to know the latest cervical cancer survival at Cipto Mangunkusumo Hospital (CM Hospital) -which is the largest national referral hospital -and to assess the prognostic factors associated with the disease.
METHODS
This study was a retrospective cohort study. All patients diagnosed as cervical cancer in CM Hospital on [2005] [2006] were included in this study. Data were acquired from oncology gynecology registry, surgery list, and radiotherapy registration database. Only patients with histopathology confirmed cervical cancer and who had available medical record were enrolled. Double primer and secondary cervical cancer were excluded. Patients who did not receive any therapy at CM hospital or whom already given therapy at other hospital were also excluded. This study has been approved by the Ethics Committee of Medical Faculty of Medicine, Universitas Indonesia (Reg. No 67/PT 02.FK/ETIK/2012).
We collected data including age, educational level, insurance coverage, place of residence, and phone number from the medical record. Clinical data included FIGO stage, tumor size, histopathology type, tumor differentiation, treatment modality, and completion of therapy. The recorded dates were time of diagnosis, last visit or last contact date, and time of death. All patients were followed up until minimal 5 years or the patients were dead or lost to follow up. Patients, who were lost to follow up, were contacted by phone or mail to know their current condition. Patients who underwent all treatment modality were grouped as completed therapy group. Patient received chemo-radiation therapy was classified as completed therapy if all radiotherapy sequences (external and brachytherapy) and a minimum of three series chemotherapy were performed. Patients underwent surgery were classified as completed therapy if further management plan after surgery was done, based on the histopathology result.
Data were analyzed using STATA 10. Survival analysis was conducted by using Kaplan-Meier method. The survival curves were compared using Log-rank test. Suggested prognostic factors were analyzed to get hazard ratio using Cox-regression analysis and were continued by multivariate analysis.
RESULTS
The number of cervical cancer patients at CM Hospital during 2005-2006 was 955 patients. Among these patients, a total of 447 patients met the study criteria. Patients were followed up until the event (death) or survive for minimal five years or being lost to follow up. This study found 107 patients got the event or death (23.9%), 73 patients (16.3%) were alive, and 267 patients (59.7%) were lost to follow up.
Subject characteristics are shown in table 1. Mean age of these patients was 47.5 years (SD ± 8.6) ranging from 24 to 73 years. Most patients had education length for 12 years or less, lived in Jabodetabek (Jakarta, Bogor, Tangerang, Bekasi) and were supported by national insurance such as GAKIN or Jamkesmas.
Median survival time for cervical cancer was 63 months with overall survival rate at year 1, 2, and 5 were 84%, 70%, and 52%, respectively. Age, education, place of residence, and medication funding was not associated with overall survival from the Log-rank test.
Most patients came at late stage, with tumor diameter > 4 cm, and had squamous cell carcinoma as shown on the Table 2 . Half of these patients completed treatment protocol. Most of the patients received chemo-radiation as therapy protocol (73.8%), followed by surgery combined chemo-radiation (8.9%), radiotherapy only (7.4%), surgery combined radiotherapy (5.8%), and surgery only (4.5%).
Survival rate in each FIGO stage is shown on figure 1. It is clearly shown that survival probability decreased with increased FIGO stage, proven by Log-rank test (p < 0.001). Stage IV had five-fold risk for mortality compared with stage I (Table 2) . Incomplete therapy was also a significant factor showing worse survival probability compared with the complete one (Logrank test, p < 0.001).
Kaplan-Meier survival curve of histopathology type showed different tendencies on survival probability (Log-rank test, p = 0.09). Bivariate analysis revealed that lesser types of pathology (others) such as neuroendocrine, small cell carcinoma, glassy cell; had higher hazard ratio compared with squamous cell carcinoma (HR = 2.85, p = 0.024). The survival curve on tumor differentiation has a trend to be different (Log-rank test, p = 0.07). Eventhough not statistically significant, poor differentiation seemed to have higher hazard ratio compared with squamous cell carcinoma (HR = 1.71, p = 0.071).
Multivariate analysis was conducted involving stage, tumor size, histopathology type, tumor differentiation, and completion of therapy. Independent prognostic factors were FIGO stage, tumor differentiation, and completion of therapy (Table 3) .
DISCUSSION
There were improvements in survival rate for cervical cancer patients in our institution over ten year period. Median survival time and overall five-years survival rate in 1997 were 13 months and 30%, while in this study were 63 months and 52%. Our results in this study were still below the FIGO report, which the 5-years survival rate probability on stage I was 75.7% -97.5%, stage II 65.8%-73.4%, stage III 39.7-41.5% and stage IV 9.3-22%. This differences presumably due to the lower prevalence of early stage (30.6%) in this study than FIGO report (53.45%).
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Based on multivariate analysis, there were several factors independently associated with decreased survival such as late FIGO stages, poor tumor differentiation, and incomplete therapy. Consistent with other studies, increased stage will upscale hazard ratio in cervical cancer patients. In this study, Hazard Ratio (HR) for stage III and IV compared to stage I were 3.27 (95% CI 1.789-5.994) and 6.44 (95% CI 2.064-10.092). These results were similar with the result at CM Hospital in 1997. 3, 6, 7 Poor differentiation showed worse survival in this study and was proven as independent factor by multivariate analysis. This result was consistent with other studies. 8, 9 Incomplete therapy, consistent with previous study at CM Hospital, also showed poorer prognosis. Patients who received incomplete therapy were two times more likely to die than those whom Table 3 . Multivariate analysis of prognostic factors for cervical cancer survival * The result was statistically significant . Although the number of patients completing therapy decreased (82.2% to 70.47%), overall survival probability was increased, either in completed or incomplete group. As mentioned before, this might be partially explained due to improved services quality. 3 In this study, age, education length, and medication funding did not appear to be significant factors for survival rate. Some studies abroad reported that these variables were associated with cervical cancer survival.
8,10
Histopathology types were not associated with survival in this study. Squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma had similar survival rate. Data from several studies showed controversial result concerning association between histopathology types of cervical cancer with survival. Adenocarcinoma was reported to have poorer prognosis than squamous cell carcinoma, 5, 11 but other studies reported no differences. 12,13 FIGO reported other types of histopathology have poor prognosis, while in this study there was also a tendency towards poorer prognosis (HR 2.62, 95% CI 1.14 -7.09). However, this was not statistically significant on multivariate analysis (HR 2.2, 95% CI 0.350 -19.536). This finding might be due to small sample size. 5 In conclusion, median survival time of cervical cancer patients was 63 months. Overall five years survival rate for cervical cancer patients at Cipto Mangunkusumo Hospital was 52%. The five years survival rate probability for stage I, II, III, and IV were 73%, 52%, 36%, and undetected, consecutively. There were improvements in overall survival, compared with previous data in 1997. Independent prognostic factors in this study were stage, tumor differentiation, and completion of therapy.
